An Evaluation of Simvastatin 20 mg Plus Omacor [omega-3 ethylester concentrate] 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia.

Trial Profile

An Evaluation of Simvastatin 20 mg Plus Omacor [omega-3 ethylester concentrate] 4 g Compared to Simvastatin 20 mg Plus Placebo in Subjects With Mixed Dyslipidemia.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Omega-3-acid ethyl esters; Simvastatin
  • Indications Dyslipidaemias; Hyperlipoproteinaemia type V
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Aug 2008 Primary endpoint 'Non high density lipoprotein cholesterol' has been met.
    • 16 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top